GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Institutional Ownership

Avalo Therapeutics (STU:C6K0) Institutional Ownership : 0.96% (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avalo Therapeutics's institutional ownership is 0.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avalo Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avalo Therapeutics's Float Percentage Of Total Shares Outstanding is 100.40%.


Avalo Therapeutics Institutional Ownership Historical Data

The historical data trend for Avalo Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Institutional Ownership Chart

Avalo Therapeutics Historical Data

The historical data trend for Avalo Therapeutics can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 2.99 0.18 1.83 1.89 2.64 2.75 2.75 0.81 0.96 0.96

Avalo Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Avalo Therapeutics (STU:C6K0) Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Avalo Therapeutics (STU:C6K0) Headlines

No Headlines